A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study of Gantenerumab in Patients With Prodromal to Mild Alzheimer's Disease

Grants and Contracts Details

StatusFinished
Effective start/end date11/29/187/31/19

Funding

  • Inc Research Inc: $2,256.00